-
Mashup Score: 0
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the filing of an Investigational Device Exemption (IDE) application to gain FDA approval to conduct the clinical study, “Safe and Timely Antithrombotic Removal – Direct Oral…
Source: finance.yahoo.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 0
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that the Company has been granted a second Breakthrough Device designation for its DrugSorb-ATR Antithrombotic Removal System by the U.S. Food and Drug Administration (FDA)….
Source: finance.yahoo.comCategories: Cardiologists, Latest HeadlinesTweet-
#Cytosorbent gains 2nd FDA breakthrough device designation for its lifesaving technology for removing antithrombotic drugs during cardiopulmonary bypass at #heartsurgery. #CTSO @CTSO https://t.co/xRPr2VOZ3D via @Yahoo
-
-
Mashup Score: 0Blood purification device for coronavirus patients granted emergency FDA approval: CytoSorbents CEO - 4 year(s) ago
With the EUA, CytoSorb can now be made available through commercial sales to all U.S. hospitals for use in patients 18 years of age and older with confirmed COVID-19 admitted to the ICU confirmed or imminent respiratory failure who have a multitude of other conditions including early acute lung injury (ALI), acute respiratory distress syndrome (ARDS), and severe and/or life-threatening disease….
Source: graffiotech.comCategories: CardiologistsTweet-
Cytosorb, a blood purification device for coronavirus patients, has bee granted emergency FDA approval. It is designed to be used with ECMO or CRRT: https://t.co/36IbiCRyME #CTSO https://t.co/PDWnGc7BEl
-
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on #Apixaban and #Rivaroxaban Removal by the DrugSorb-ATR™ Antithrombotic Removal System During Urgent Cardiothoracic Surgery #CTSO https://t.co/Zkl3HJUBIJ via @Yahoo